バイオマーカーの世界市場規模：製品タイプ別、用途別、適応疾患別、地域別、範囲および予測

バイオマーカーの市場規模と予測

バイオマーカーの市場規模は、2023年に711億9,000万米ドルと評価され、2024年から2031年にかけて15.8%のCAGRで成長し、2031年には2,301億8,000万米ドルに達すると予測されています。バイオマーカーとは、血液や尿などの生物学的サンプルから発見される測定可能な徴候で、生物学的プロセス、状態、疾患に関する情報を明らかにします。これらのマーカーには、血圧や心拍数のような身体的特徴だけでなく、タンパク質、核酸、代謝物のような物質も含まれます。バイオマーカーは、病気の診断、予後予測、治療モニタリングなど、医学における様々な応用があります。臨床の場面では、バイオマーカーは病気の早期発見、病気の開発の追跡、治療効果の評価において臨床医を支援します。

さらに、バイオマーカーは臨床試験の患者選択、実験的治療の安全性と有効性のモニタリングに役立つため、医薬品開発においても重要です。

世界のバイオマーカー市場力学

主な市場促進要因

医療技術の進歩：

ゲノム、プロテオミクス、メタボロミクスの開発により、新たなバイオマーカーの開発と確認が可能になりつつあります。これらの技術は病気の診断、予後、モニタリングを改善し、臨床診療や研究におけるバイオマーカーの採用を増加させています。

慢性疾患の有病率の増加：

がん、心血管疾患、神経疾患などの慢性疾患の有病率が世界的に高まっているため、早期発見と個別化治療レジメンが必要とされています。その結果、バイオマーカーは病気のリスク、進行、治療効果を判断する上で重要な役割を果たし、市場の成長を後押ししています。

個別化医療への注目の高まり：

患者一人ひとりの特性に合わせた個別化医療が重視されるようになっています。そのため、バイオマーカーはこのアプローチにおいて重要です。なぜなら、バイオマーカーは薬に対する個々の反応を予測するのに役立ち、その結果、より効果的で安全な治療が可能になるからです。

バイオマーカー研究に対する政府と民間の資金援助：

バイオマーカー研究に対する政府および民間セクターの投資が市場を牽引しています。このような資金提供は、アンメットメディカルニーズに対応し、ヘルスケアの転帰を改善する新規バイオマーカーの創出と検証を促進します。

主な課題：

バイオマーカー開発に伴う高コスト：

バイオマーカーの開発と検証には、最新技術と長期の臨床試験が必要なため、多額の資金が必要となります。こうした高コストが新規事業参入や新たなバイオマーカーの発見を阻み、市場の成長を制限しています。

倫理とプライバシーの問題：

バイオマーカーの使用には遺伝子情報の収集と解析が必要であり、遺伝子データをめぐるプライバシー、許可、倫理的問題が高まる。そのため、データの機密性と倫理的利用を維持しながらこれらの課題に対処することが、同市場における重要な課題となっています。

標準化の欠如：

バイオマーカー開発、バリデーション、アプリケーションのための標準化されたプロセスは、様々なプラットフォームや研究所に存在しないです。この不一致が結果の予測不可能性を引き起こし、バイオマーカーの信頼性と比較可能性を低下させています。

主な動向

リキッドバイオプシーの拡大：

リキッドバイオプシーは、生理的液体に含まれるバイオマーカーを用いて病気を検出・モニタリングする非侵襲的な方法として人気を集めています。使い勝手がよく、病気の発症をリアルタイムで知ることができるため、がんやその他の慢性疾患で人気が高まっています。

マルチ・オミクス・アプローチ：

マルチオミクス（ゲノミクス、プロテオミクス、メタボロミクス）の利用が増加しており、病気の原因をより深く理解することができます。この包括的な手法により、より正確で予測可能なバイオマーカーの同定が可能となり、個別化治療レジメンの改善につながります。

コラボレーションとパートナーシップ：

製薬企業、バイオテクノロジー企業、研究機関は、バイオマーカーの開発と実用化を加速するために、ますます協力するようになっています。このような協力関係は、知識、リソース、技術の交換を促進し、新しいバイオマーカーの市場導入を早める。

目次

第1章 世界のバイオマーカー市場：イントロダクション

• 市場概要
• 調査範囲
• 前提条件

第2章 エグゼクティブサマリー

第3章 VERIFIED MARKET RESEARCHの調査手法

• データマイニング
• バリデーション
• 一次資料
• データソース一覧

第4章 世界のバイオマーカー市場展望

• 概要
• 市場力学
  • 促進要因
  • 抑制要因
  • 機会
• ポーターのファイブフォースモデル
• バリューチェーン分析
• 規制の枠組み

第5章 バイオマーカーの世界市場：適応疾患別

• 概要
• がん
• 感染症
• 免疫疾患
• 神経疾患
• 心血管疾患
• その他

第6章 バイオマーカーの世界市場：用途別

• 概要
• 診断
• 創薬・開発
• 個別化医療
• 疾患リスク評価
• その他

第7章 バイオマーカーの世界市場：タイプ別

• 概要
• 安全性バイオマーカー
• 有効性バイオマーカー
• 予測バイオマーカー
• 代替バイオマーカー
• 薬力学バイオマーカー
• 予後予測バイオマーカー
• 検証バイオマーカー

第8章 バイオマーカーの世界市場：製品別

• 概要
• 消耗品
• サービス
• ソフトウェア

第9章 バイオマーカーの世界市場：地域別

• 概要
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • その他欧州
• アジア太平洋
  • 中国
  • 日本
  • インド
  • その他アジア太平洋地域
• 世界のその他の地域
  • ラテンアメリカ
  • 中東・アフリカ

第10章 世界のバイオマーカー市場：競合情勢

• 概要
• 企業市場シェア
• ベンダー情勢
• 主な開発戦略

第11章 企業プロファイル

• Abbott Laboratories
• F. Hoffmann-La Roche Ltd
• Siemens Healthineers AG
• Danaher Corporation
• Thermo Fisher Scientific Inc.
• Illumina Inc.
• Merck KGaA
• Johnson & Johnson
• PerkinElmer Inc.
• QIAGEN N.V.

第12章 主な発展

• 製品の上市／開発
• 合併と買収
• 事業拡大
• パートナーシップと提携

第13章 付録

• 関連調査

Biomarkers Market Size And Forecast

Biomarkers Market size was valued at USD 71.19 Billion in 2023 and is projected to reach USD 230.18 Billion by 2031, growing at a CAGR of 15.8% from 2024 to 2031. Biomarkers are measurable signs discovered in biological samples like blood or urine that reveal information about a biological process, state, or disease. These markers can include substances like proteins, nucleic acids, or metabolites, as well as physical features like blood pressure or heart rate. Biomarkers have a variety of applications in medicine, including disease diagnosis, prognosis, and treatment monitoring. In clinical contexts, biomarkers assist clinicians in early disease detection, tracking disease development, and assessing treatment response.

Furthermore, biomarkers are important in drug development because they help with patient selection for clinical trials as well as monitoring the safety and efficacy of experimental treatments.

Global Biomarkers Market Dynamics

The key market dynamics that are shaping the Biomarkers Market include:

Key Market Drivers:

Advancements in Medical Technologies:

Developments in genomes, proteomics, and metabolomics are allowing for the development and confirmation of new biomarkers. These technologies improve illness diagnosis, prognosis, and monitoring, increasing the adoption of biomarkers in clinical practice and research.

Growing Prevalence of Chronic Diseases:

The increasing prevalence of chronic diseases such as cancer, cardiovascular disease, and neurological problems worldwide needs early detection and personalized treatment regimens. As a result, biomarkers play an important role in determining illness risk, progression, and treatment response, fueling market growth.

Increased Focus on Personalized Medicine:

There is an increasing emphasis on personalized medicine, which tailors medical therapy to the unique characteristics of each patient. Thus, biomarkers are important in this approach because they assist in predicting individual responses to medications, resulting in more effective and safer treatments.

Government and Private Funding for Biomarker Research:

Government and private sector investments in biomarker research are driving the market ahead. This funding promotes the creation and validation of novel biomarkers, that address unmet medical needs and improve healthcare outcomes.

Key Challenges:

High Costs Associated with Biomarker Development:

The development and validation of biomarkers require significant financial commitment, owing to the necessity for modern technologies and lengthy clinical trials. These high prices impede the entry of new businesses and the discovery of new biomarkers, limiting market growth.

Ethical and Privacy Concerns:

The use of biomarkers requires the collection and analysis of genetic information demanding rise in privacy, permission, and ethical questions surrounding genetic data. Thus, addressing these issues while maintaining data confidentiality and ethical use presents a significant challenge in the market.

Lack of Standardization:

There is an absence of standardized processes for biomarker development, validation, and application across various platforms and laboratories. This discrepancy causes unpredictability in outcomes, reducing the reliability and comparability of biomarkers.

Key Trends:

Expansion in Liquid Biopsy:

Liquid biopsy is gaining popularity as a non-invasive way to detect and monitor diseases using biomarkers found in physiological fluids. Its ease of use and capacity to provide real-time insights into illness development make it popular in cancer and other chronic diseases.

Multi-Omics Approaches:

The use of multi-omics (genomics, proteomics, and metabolomics) is increasing, offering a more thorough understanding of disease causes. This comprehensive method enables the identification of more precise and predictive biomarkers, hence improving personalized treatment regimens.

Collaborations and Partnerships:

Pharmaceutical businesses, biotechnology firms, and research institutes are increasingly working together to speed biomarker development and implementation. These collaborations promote the exchange of knowledge, resources, and technology, hastening the introduction of new biomarkers to the market.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

Global Biomarkers Market Regional Analysis

Here is a more detailed regional analysis of the Biomarkers Market:

North America:

According to Verified Market Research, North America is estimated to dominate in Biomarkers Market over the forecast period. North America, particularly the United States, has a robust research infrastructure that includes prestigious universities, research institutes, and biotech firms. This promotes creativity and aids in the discovery and development of new biomarkers.

The region has one of the world's highest healthcare expenditures, resulting in major investments in modern diagnostic tools and personalized therapy. This financial commitment promotes the use and integration of biomarkers in clinical practice.

The establishment of a strong and supportive regulatory environment, as demonstrated by authorities such as the FDA, supports the dependability and safety of biomarker-based diagnostic and therapeutic products. This regulatory environment promotes the development and commercialization of biomarker technology.

Furthermore, personalized medicine is becoming increasingly popular among North American healthcare providers and patients. This demand promotes the use of biomarkers for precise diagnosis, treatment planning, and monitoring, accelerating market expansion in this region.

Asia Pacific:

Asia Pacific is estimated to exhibit the highest growth in the market during the forecast period. Many Asia Pacific countries are experiencing a strong economic expansion, thereby, spurring up healthcare investment. This economic boom allows for increased spending on new healthcare technologies, such as biomarkers for diagnosis and treatment.

Chronic ailments such as cancer, cardiovascular disease, and diabetes are becoming increasingly prevalent in the region. This increased prevalence is fueling the desire for early detection and personalized treatments, which require biomarkers.

Furthermore, the Asia Pacific region is growing its investment in R&D, particularly in the biotechnology and pharmaceutical sectors. This investment promotes the discovery and development of new biomarkers, which is aided by increased academic-industrial collaborations.

Europe:

European countries benefit from favorable regulatory laws and significant financing opportunities for research and development from the European Union and national governments. This environment promotes the advancement and acceptance of biomarker technology.

Europe boasts some of the world's most modern healthcare systems, with widespread access to cutting-edge medical technologies. This infrastructure facilitates the integration of biomarkers into ordinary clinical practice, hence improving patient care and treatment outcomes.

Chronic diseases are prevalent in Europe, with cancer and cardiovascular disease being among the most common. The necessity for early detection, effective treatment, and management of these illnesses is driving the demand for biomarkers in clinical settings.

Furthermore, the region has a collaborative research environment, which is distinguished by relationships between university, biotech, and pharmaceutical businesses. This collaboration speeds up biomarker research and development, encouraging innovation and enabling the translation of research discoveries into clinical applications.

Global Biomarkers Market: Segmentation Analysis

The Global Biomarkers Market is segmented based on Product, Type, Application, Disease Indication, And Geography.

Biomarkers Market, By Product

• Consumables
• Services
• Software

Based on Product, the market is segmented into Consumables, Services, and Software. The consumables segment is estimated to dominate the Biomarkers Market due to the ongoing requirement for consumables in a variety of diagnostic and research applications. Consumables such as reagents, kits, and assays are required for the detection and assessment of biomarkers on a variety of platforms, including ELISA, PCR, and next-generation sequencing. Their broad use in clinical laboratories, research institutions, and pharmaceutical businesses generates high demand.

Biomarkers Market, By Type

• Safety Biomarkers
• Efficacy Biomarkers
• Predictive Biomarkers
• Surrogate Biomarkers
• Pharmacodynamics Biomarkers
• Prognostic Biomarkers
• Validation Biomarkers

Based on Type, the market is segmented into Safety Biomarkers, Efficacy Biomarkers, Predictive Biomarkers, Surrogate Biomarkers, Pharmacodynamics Biomarkers, Prognostic Biomarkers, and Validation Biomarkers. The safety biomarker segment is estimated to dominate the Biomarkers Market due to its critical role in analyzing the potential dangers and toxicological consequences of novel medication candidates and therapeutic interventions. Safety biomarkers are critical throughout the medication development process, from early preclinical research to late-stage clinical trials and post-market surveillance.

Biomarkers Market, By Application

• Diagnostics
• Drug Discovery & Development
• Personalized Medicine
• Disease Risk Assessment
• Others

Based on Application, the market is segmented into Diagnostics, Drug Discovery & Development, Personalized Medicine, Disease Risk Assessment, and Others. The diagnostic segment is estimated to dominate the Biomarkers Market. This dominance is primarily due to the increased use of biomarkers in the early detection, diagnosis, and monitoring of a wide range of diseases, including cancer, cardiovascular disease, neurological disorders, and infectious diseases. Biomarkers provide a non-invasive, accurate, and efficient method of identifying diseases, considerably improving patient outcomes by allowing for timely and targeted therapy. The increased global frequency of chronic diseases, combined with advances in diagnostic technologies and a greater emphasis on preventative healthcare, propelling demand for diagnostic biomarkers.

Biomarkers Market, By Disease Indication

• Cancer
• Infectious Diseases
• Immune Disorders
• Neurological Disorders
• Cardiovascular Disorders
• Others

Based on Disease Indication, the market is segmented into Cancer, Infectious Diseases, Immune Disorders, Neurological Disorders, Cardiovascular Disorders, and Others. The cancer segment is estimated to dominate the market over the forecast period due to the rising global incidence and prevalence of cancer, which has resulted in significant expenditure in cancer research and diagnostics. Biomarkers are critical for early detection, diagnosis, prognosis, and monitoring of cancer treatment and progression. The quest for personalized treatment and targeted therapy in oncology increases the need for precise and reliable biomarkers.

Key Players

• The "Biomarkers Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are
• Abbott Laboratories, F. Hoffmann-La Roche Ltd, Siemens Healthineers AG, Danaher Corporation, Thermo Fisher Scientific Inc., Illumina Inc., Merck KGaA, Johnson & Johnson, PerkinElmer Inc., QIAGEN N.V., DiaSorin S.p.A., Myriad Genetics, Luminex Corporation, Becton, Dickinson and Company, Agilent Technologies Inc., Bio-Rad Laboratories, Quest Diagnostics Incorporated, Enzo Biochem, and ARUP Laboratories.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

• Biomarkers Market Recent Developments
• In February 2024, Abbott announced a collaboration with the Mayo Clinic to develop and commercialize blood tests for Alzheimer's disease early detection.
• In February 2024, F. Hoffmann-La Roche received FDA approval for its Elecsys Signet BRAF V600E Mutation Test, which will help identify individuals with melanoma who may benefit from targeted therapy.
• In February 2024, Siemens Healthineers introduced Atellica IM, a new immunoassay analyzer that aims to increase biomarker testing efficiency and accuracy.
• In February 2024, Danaher Corporation announced the acquisition of Beckman Coulter Life Sciences, a company that specializes in life sciences research tools and diagnostics, such as biomarker assays.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL BIOMARKERS MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL BIOMARKERS MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis
• 4.5 Regulatory Framework

5 GLOBAL BIOMARKERS MARKET, BY DISEASE INDICATION

• 5.1 Overview
• 5.2 Cancer
• 5.3 Infectious Diseases
• 5.4 Immune Disorders
• 5.5 Neurological Disorders
• 5.6 Cardiovascular Disorders
• 5.7 Others

6 GLOBAL BIOMARKERS MARKET, BY APPLICATION

• 6.1 Overview
• 6.2 Diagnostics
• 6.3 Drug Discovery & Development
• 6.4 Personalized Medicine
• 6.5 Disease Risk Assessment
• 6.6 Others

7 GLOBAL BIOMARKERS MARKET, BY TYPE

• 7.1 Overview
• 7.2 Safety Biomarkers
• 7.3 Efficacy Biomarkers
• 7.4 Predictive Biomarkers
• 7.5 Surrogate Biomarkers
• 7.6 Pharmacodynamics Biomarkers
• 7.7 Prognostic Biomarkers
• 7.8 Validation Biomarkers

8 GLOBAL BIOMARKERS MARKET, BY PRODUCT

• 8.1 Overview
• 8.2 Consumables
• 8.3 Services
• 8.4 Software

9 GLOBAL BIOMARKERS MARKET, BY GEOGRAPHY

• 9.1 Overview
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
  • 9.2.3 Mexico
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 U.K.
  • 9.3.3 France
  • 9.3.4 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Rest of Asia Pacific
• 9.6 Rest of the World
  • 9.6.1 Latin America
  • 9.6.2 Middle East & Africa

10 GLOBAL BIOMARKERS MARKET COMPETITIVE LANDSCAPE

• 10.1 Overview
• 10.2 Company Market Share
• 10.3 Vendor Landscape
• 10.4 Key Development Strategies

11 COMPANY PROFILES

• 11.1 Abbott Laboratories
  • 11.1.1 Overview
  • 1.1.2 Financial Performance
  • 11.1.3 Product Outlook
  • 11.1.4 Key Developments
• 11.2 F. Hoffmann-La Roche Ltd
  • 11.2.1 Overview
  • 11.2.2 Financial Performance
  • 11.2.3 Product Outlook
  • 11.2.4 Key Developments
• 11.3 Siemens Healthineers AG
  • 11.3.1 Overview
  • 11.3.2 Financial Performance
  • 11.3.3 Product Outlook
  • 11.3.4 Key Developments
• 11.4 Danaher Corporation
  • 11.4.1 Overview
  • 11.4.2 Financial Performance
  • 11.4.3 Product Outlook
  • 11.4.4 Key Developments
• 11.5 Thermo Fisher Scientific Inc.
  • 11.5.1 Overview
  • 11.5.2 Financial Performance
  • 11.5.3 Product Outlook
  • 11.5.4 Key Developments
• 11.6 Illumina Inc.
  • 11.6.1 Overview
  • 11.6.2 Financial Performance
  • 11.6.3 Product Outlook
  • 11.6.4 Key Developments
• 11.7 Merck KGaA
  • 11.7.1 Overview
  • 11.7.2 Financial Performance
  • 11.7.3 Product Outlook
  • 11.7.4 Key Developments
• 11.8 Johnson & Johnson
  • 11.8.1 Overview
  • 11.8.2 Financial Performance
  • 11.8.3 Product Outlook
  • 11.8.4 Key Developments
• 11.9 PerkinElmer Inc.
  • 11.9.1 Overview
  • 11.9.2 Financial Performance
  • 11.9.3 Product Outlook
  • 11.9.4 Key Developments
• 11.10 QIAGEN N.V.
  • 11.10.1 Overview
  • 11.10.2 Financial Performance
  • 11.10.3 Product Outlook
  • 11.10.4 Key Developments

12 KEY DEVELOPMENTS

• 12.1 Product Launches/Developments
• 12.2 Mergers and Acquisitions
• 12.3 Business Expansions
• 12.4 Partnerships and Collaborations

13 Appendix

• 13.1 Related Research